EUVIMEDEUVIMED entdecken
Crossref

Extraaxial Poorly Differentiated Chordoma: Clinicopathologic and Molecular Genetic Characterization

William J Sande, Andrew L Folpe, Paige O'Connor, Daniel Graham, Jeremy F Molligan, Ying-Chun Lo, Yvonne Y Cheung, Baptiste Ameline, Daniel Baumhoer, Dorothee Harder, Kevin A Raskin, Christopher W Mount und 6 weitere

Modern Pathology · 2025-03 · 38 (3) · 100664

DOI: 10.1016/j.modpat.2024.100664 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2025-03. Verfasst von William J Sande und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. Hauptthemen laut MEDLINE: Chordoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poorly differentiated chordoma (PDC) is an aggressive subtype of chordoma characterized by SMARCB1 (INI1) loss and a dismal prognosis. It typically involves the axial skeleton, most commonly the skull base and the cervical spine. To our knowledge, only 5 cases of extraaxial PDC (EAPDC) have been reported, and the natural history of these tumors is not fully understood. We studied 6 cases of EAPDC, with the goal of better understanding these exceptionally rare tumors. The tumors occurred in 4 women and 2 men, ranging from 37 to 68 years of age (median, 57.5 years) and involved or originated in the left knee joint (3 cases), right knee joint (2 cases), and right wrist (1 case). Grossly, all were solid and lobulated, with areas of necrosis. Histologically, the tumors were identical to axial PDC, with sheets and lobules of overtly malignant-appearing epithelioid-to-rhabdoid cells with prominent nucleoli. Mitotic activity and necrosis were present. By immunohistochemistry, all cases expressed keratins and brachyury and were SMARCB1 deficient. Molecular genetic analysis identified SMARCB1 loss-of-function alterations in 4 of the tested cases, including mutations (2 cases) and copy number loss (2 cases). DNA methylation profiling of 4 cases of EAPDC showed clustering with axial PDC. Clinical follow-up (6 patients; median, 11.5 months; range, 1-26 months) showed 4 patients to have received transfemoral amputation and 1 extraarticular resection. None received neoadjuvant radiotherapy; 1 received neoadjuvant chemotherapy and 1 adjuvant chemotherapy/immunotherapy. Local recurrences were seen in 2 patients at 7 and 8 months; 3 patients developed metastases 7-11 months after surgery. Two patients were alive with metastatic disease (at 7 and 13 months), 1 died of disease (20 months), and 3 were disease free (1-26 months). We conclude that EAPDC are aggressive malignancies with an unusual predilection for the knee joint and unknown pathogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChordomaHumansMaleFemaleMiddle AgedAgedAdultSMARCB1 ProteinBiomarkers, TumorKnee JointImmunohistochemistryMutationBrachyury Protein

Stichwörter der Autor:innen

INI1SMARCB1chordomaextraaxialimmunohistochemistrymethylationmolecular geneticspoorly differentiated chordoma

Substanzen

SMARCB1 ProteinSMARCB1 protein, humanBiomarkers, TumorBrachyury Protein

Autor:innen und Institutionen

  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, New Hampshire.
  • Clinical Labs of Hawaii, Straub Hospital, John A. Burns School of Medicine, Honolulu, Hawai.
  • Department of Radiology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.
  • Bone Tumor Reference Center at the Institute for Medical Genetics and Pathology, University Hospital and University of Basel, Basel, Switzerland.
  • Bone Tumor Reference Center at the Institute for Medical Genetics and Pathology, University Hospital and University of Basel, Basel, Switzerland; Basel Research Centre for Child Health, Basel, Switzerland.

Zitieren

APA

Sande, W. J., Folpe, A. L., O'Connor, P., Graham, D., Molligan, J. F., Lo, Y. C., Cheung, Y. Y., Ameline, B., Baumhoer, D., Harder, D., Raskin, K. A., Mount, C. W., Hung, Y. P., Nielsen, G. P., Kerr, D. A., Buehler, D., Wenger, D. E., & Thangaiah, J. J. (2025). Extraaxial Poorly Differentiated Chordoma: Clinicopathologic and Molecular Genetic Characterization. Modern Pathology, 38(3), 100664. https://doi.org/10.1016/j.modpat.2024.100664

Vancouver

Sande WJ, Folpe AL, O'Connor P, Graham D, Molligan JF, Lo YC, et al. Extraaxial Poorly Differentiated Chordoma: Clinicopathologic and Molecular Genetic Characterization. Modern Pathology. 2025;38(3):100664. doi:10.1016/j.modpat.2024.100664

BibTeX
@article{Sande2025,
  author = {Sande, William J and Folpe, Andrew L and O'Connor, Paige and Graham, Daniel and Molligan, Jeremy F and Lo, Ying-Chun and Cheung, Yvonne Y and Ameline, Baptiste and Baumhoer, Daniel and Harder, Dorothee and Raskin, Kevin A and Mount, Christopher W and Hung, Yin P and Nielsen, Gunnlaugur Petur and Kerr, Darcy A and Buehler, Darya and Wenger, Doris E and Thangaiah, Judith Jebastin},
  title = {Extraaxial Poorly Differentiated Chordoma: Clinicopathologic and Molecular Genetic Characterization},
  journal = {Modern Pathology},
  year = {2025},
  volume = {38},
  number = {3},
  pages = {100664},
  doi = {10.1016/j.modpat.2024.100664}
}
Kostenlos starten →